SAN FRANCISCO, Calif., United States – May 5, 2026
Verana Health Inc. has introduced advanced functionality across its Site Explorer and Verana Trial Connect (VTC) platforms, aiming to transform site selection and patient enrollment in clinical trials through real-world data (RWD). The update delivers end-to-end transparency, real-time dashboards, and automated patient identification, enabling sponsors and CROs to accelerate enrollment timelines, improve site performance, and reduce costly delays. By leveraging large-scale de-identified patient datasets and AI-driven analytics, the company is addressing long-standing inefficiencies in clinical research, where manual processes and poor site visibility often hinder trial success.
Data-Driven Platforms Address Enrollment Bottlenecks
Traditional clinical trial enrollment is fundamentally inefficient. It relies heavily on manual chart reviews, clinician referrals, and limited visibility into real patient availability, which leads to underperforming sites and missed recruitment targets. Verana Health Inc. is directly targeting these weaknesses by integrating real-world data insights into its Site Explorer and VTC tools, allowing sponsors to identify high-performing sites with relevant patient populations before trial initiation. The platforms provide real-time dashboards with de-identified screening activity, enabling stakeholders to monitor enrollment progress across multiple sites simultaneously, making faster and more informed operational decisions. This is a critical shift from reactive to proactive, data-driven trial management.
AI and Real-World Data Power Faster Patient Matching
The upgraded Site Explorer platform allows sponsors to analyze inclusion and exclusion criteria impact on eligible patient pools, ensuring better trial feasibility assessments. Meanwhile, Verana Trial Connect (VTC) integrates directly with electronic health records (EHRs) to automate patient pre-screening and eligibility checks, significantly reducing the need for manual intervention. This automation enables research teams to identify suitable candidates faster and with higher accuracy, cutting down recruitment timelines and improving study efficiency. The company’s access to over 95 million de-identified patient records, sourced through partnerships with the American Academy of Ophthalmology IRIS® Registry and the American Urological Association AQUA Registry, provides a massive data advantage, allowing for precise targeting of patient cohorts across multiple therapeutic areas.
Advertisement
Strategic Impact on Clinical Research Ecosystem
Verana Health Inc. is positioning itself at the intersection of digital health, AI, and clinical research, where real-world evidence is becoming essential for drug development and regulatory decision-making. By improving site selection accuracy and patient enrollment efficiency, the company’s technology can help reduce trial costs, shorten development timelines, and increase the probability of successful outcomes. This is particularly important as clinical trials become more complex and competitive, with limited patient pools and increasing regulatory expectations. The ability to continuously refresh longitudinal datasets and provide actionable insights in real time gives sponsors a decisive operational edge, signaling a broader industry transition toward data-centric clinical trial execution models.
Source: Verana Health press release
